Chemokine Gene-modified Cells for Cancer Immunotherapy
Described herein are methods of cancer immunotherapy, particularly compositions comprising genetically-modified cells that express macrophage colony stimulating factor (GM-CSF), CD40 ligand (CD40L), and chemokine C-C motif ligand 21 (CCL21), wherein the population of cells comprises bystander cells and target cancer cells, and methods of making these compositions and treating cancer using these compositions.
Attached files:Patents:US 20,110,059,137
Inventor(s):
ANTONIA SCOTT JOSEPH [US]; MULE JAMES J [US]
Type of Offer:
Licensing
« More Genetics Patents